The management of blood cancers has undergone significant transformations over the last decade by introduction of targeted therapies directed at critical molecular components controlling cell growth. Among several classes of innovative therapies, Bruton’s Tyrosine Kinase (BTK) inhibitors have recently emerged as therapeutic mainstays for a variety of B-cell malignancies including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and other B-cell derived cancers. Pirtobrutinib and zanubrutinib are BTK inhibitors that have been evaluated in clinical studies for various B-cell malignancies. A comparison of two novel BTK inhibitors, Pirtobrutinib vs Zanubrutinib, in clinical development for a variety of B-cell derived blood cancers will thus be critical for practicing clinicians to incorporate latest advancements in clinical management of these cancers.

Both pirtobrutinib and zanubrutinib target the BTK protein in patients with B-cell malignancies; however, they differ in their binding mechanisms, clinical development, and the patient populations in which they have been studied. This article provides an overview of these therapies and summarizes clinical research evaluating their use in both treatment-naïve and previously treated patients.

Understanding BTK Inhibitors

Bruton’s tyrosine kinase (BTK) is an enzyme involved in signaling pathways that support the growth, survival, and maturation of B cells. In certain B-cell malignancies, BTK signaling may contribute to the survival and proliferation of malignant B cells. BTK inhibitors are therapies that target BTK and disrupt these signaling pathways. BTK inhibitors work by blocking BTK-mediated signaling pathways involved in the growth and survival of malignant B cells in certain blood cancers.

BTK inhibitors have paved the way for an alternative therapeutic strategy for managing B-cell malignancies, that of targeted therapy. Newer oral drugs such as the BTK inhibitors have the potential of providing durable disease control and have alleviated the need for traditional chemotherapeutic regimens in many patients.

Overview of Pirtobrutinib

Pirtobrutinib is a non-covalent BTK inhibitor developed to address some limitations associated with earlier BTK inhibitors. A distinguishing characteristic of pirtobrutinib is its potential to remain active against the majority of BTK mutations, including some that are developed during treatment with other BTK inhibitors. Pirtobrutinib binds to BTK in a non-covalent and reversible manner and has been evaluated for activity against both wild-type BTK and certain BTK mutations. The drug is being investigated for the treatment of several B-cell malignancies and is also being tested in combination with other agents. Early clinical trials of Pirtobrutinib have reported promising activity in patients with relapsed or refractory (RR) B-cell malignancies, including CLL.

Pirtobrutinib has been evaluated in clinical studies involving patients with B-cell malignancies who have previously received BTK inhibitor therapy, including those with disease progression following prior treatment. It is also being investigated in treatment-naïve patients and in combination with other therapies across various B-cell malignancies.

Overview of Zanubrutinib

Zanubrutinib is a second-generation, covalent BTK inhibitor with high selectivity for the BTK enzyme, reducing non-specific (off-target) effects reported in some patients treated with first-generation BTK inhibitors.

The efficacy and durability of Zanubrutinib treatment have been evaluated in several indications for blood cancer. Hence Zanubrutinib has become a treatment option for patients suffering from such types of cancer. The high selectivity of Zanubrutinib for BTK may be associated with a favorable safety profile of the drug and good efficacy.

Further studies are planned for Zanubrutinib as a single agent as well as in combination with other treatments for blood cancers to try to improve patient outcomes.

Pirtobrutinib vs Zanubrutinib: Mechanism of Action

Key differences in Pirtobrutinib vs Zanubrutinib include the interaction of each with the BTK enzyme.

Zanubrutinib covalently binds to the BTK protein to provide sustained inhibition of BTK enzyme activity. It has been shown to have significant selectivity with less effect on non-BTK tyrosine kinases than ibrutinib and other BTK inhibitors. The prolonged inhibition of BTK by Zanubrutinib can lead to treatment resistance in some patients who develop specific mutations in the BTK protein.

Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that has been evaluated in clinical studies involving both wild-type BTK and certain BTK mutations associated with resistance to prior BTK inhibitor therapy.

Approved and Investigational Uses

Even though Zanubrutinib and Pirtobrutinib target the same molecule (BTK) more research is still needed to uncover the full scope of potential uses for these medications.

Indications Under Investigation With Zanubrutinib Include:

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström Macroglobulinemia (WM)
• Marginal Zone Lymphoma (MZL)
• Other B-cell malignancies

Researchers continue to evaluate expanded indications through ongoing clinical trials.

Clinical Effectiveness

Clinical studies have proven that the two BTK inhibitors, Zanubrutinib and Pirtobrutinib, produce clinically meaningful responses in patients with B-cell malignancies. However, decisions on the appropriate treatment will largely depend on prior treatments, molecular characteristics of the malignancy, additional biomarker information, and patient-specific characteristics.

Zanubrutinib has shown disease control in a number of clinical settings for the treatment of B-cell malignancies, in both treatment naive and previously treated patients.

Pirtobrutinib was evaluated in patients with refractory CLL/MCL who had received prior therapy with one or more BTK inhibitors. There are ongoing comparative studies to assess the two drugs in the treatment of B-cell malignancies and to clarify their position in the current cancer therapy concept.

Safety Profiles

A comparison of pirtobrutinib and zanubrutinib should also consider the safety profiles observed in clinical studies. Both therapies are associated with adverse events, and the type and frequency of these events may vary among patients and across studies. Treatment selection and management should be individualized based on patient-specific factors, with appropriate monitoring throughout therapy.

Common Side Effects Observed in Clinical Trials:

• Fatigue
• Diarrhea
• Bruising
• Mild bleeding
• Upper respiratory infections
• Low blood cell counts
• Headache
• Muscle or joint discomfort

As with other therapies, patients should be monitored for adverse events during treatment, and appropriate management strategies may be implemented as required.

Drug Resistance and Future Treatment Strategies

The biggest development in treating blood cancer today is in understanding why patients develop resistance to BTK inhibitors while on treatment for BTK positive blood cancers.

There are instances where resistance to therapy occurs. Some of these instances are due to mutations that have occurred in the BTK protein, so that certain BTK inhibitors cannot bind to BTK. A recently developed non-covalent BTK inhibitor, Pirtobrutinib, has been shown to be effective in these cases.

There are also studies investigating the use of BTK inhibitors in combination with other targeted agents such as BCL-2 inhibitors, monoclonal antibodies and other drugs to try to decrease the occurrence of resistance allowing for deeper and longer lasting remissions.

Ongoing Clinical Research

Several clinical trials are currently exploring the use of Pirtobrutinib and Zanubrutinib in various settings as a monotherapy as well as in combination with other agents for patients with different stages of disease and treatments.

Current Research Focuses On:

• First-line treatment strategies
• Relapsed or refractory disease
• Combination therapy
• Long-term safety
• Resistance prevention
• Fixed-duration treatment approaches
• Minimal residual disease outcomes

The results from these ongoing studies will hopefully lead to a determination of the best sequencing of these agents and which individual patients may be most likely to benefit from a particular agent.

Factors Influencing Treatment Decisions

Deciding which BTK inhibitor is appropriate requires consideration of multiple factors, such as disease characteristics, treatment history, genetic abnormalities, underlying health conditions, concomitant medications, and patient goals.

Important Considerations May Include:

• Previous BTK inhibitor exposure
• Presence of resistance mutations
• Overall health status
• Cardiovascular history
• Bleeding risk
• Kidney and liver function
• Concurrent medications
• Treatment goals

Future Outlook

Research related to BTK inhibitors, now one of the most rapidly developing fields in modern hematology, is focusing on the development of novel compounds that are able to overcome resistance while having an optimal safety profile for patients.

Ongoing clinical trials will be important to continue to test novel single agents and combinations in patients with CLL and other B-cell malignancies. Continued comparison between Pirtobrutinib vs Zanubrutinib will be crucial to define the benefits of each agent and to develop the most optimal treatment strategy for individual patients.

Final Thoughts

The comparison of pirtobrutinib and zanubrutinib highlights ongoing developments in BTK inhibitor research for B-cell malignancies. Although both therapies target BTK, they differ in their binding mechanisms, clinical development, and the patient populations in which they have been studied. These distinctions may be particularly relevant when evaluating treatment approaches for patients with relapsed, refractory, or previously treated CLL.

Clinical trials are continuing to investigate pirtobrutinib and zanubrutinib in a range of B-cell malignancies. Findings from ongoing research may contribute to a better understanding of their clinical use and place within evolving treatment strategies.